HUP0302635A2 - Valpronsav foszfolipidszármazékai és ezek keveréke - Google Patents

Valpronsav foszfolipidszármazékai és ezek keveréke

Info

Publication number
HUP0302635A2
HUP0302635A2 HU0302635A HUP0302635A HUP0302635A2 HU P0302635 A2 HUP0302635 A2 HU P0302635A2 HU 0302635 A HU0302635 A HU 0302635A HU P0302635 A HUP0302635 A HU P0302635A HU P0302635 A2 HUP0302635 A2 HU P0302635A2
Authority
HU
Hungary
Prior art keywords
valproic acid
mixtures
covalently bound
pharmaceutically acceptable
phospholipid
Prior art date
Application number
HU0302635A
Other languages
English (en)
Inventor
Alexander Kozak
Original Assignee
D-Pharm Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by D-Pharm Ltd. filed Critical D-Pharm Ltd.
Publication of HUP0302635A2 publication Critical patent/HUP0302635A2/hu
Publication of HUP0302635A3 publication Critical patent/HUP0302635A3/hu
Publication of HU229320B1 publication Critical patent/HU229320B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fats And Perfumes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A találmány olyan gyógyszerkészítményre vonatkozik, amely egyfoszfolipidrészhez kovalensen kötött valpronsav vagy gyógyászatilagelfogadható származéka hatásos mennyiségét, továbbá gyógyászatilagelfogadható hordozót tartalmaz. A találmány kiterjed egy másikvalpronsavat vagy gyógyászatilag elfogadható származékát egy másikfoszfolipidrészhez kovalensen kötve tartalmazó gyógyszerkészítményre.A fenti készítmények emlősök központi idegrendszerirendellenességeinek kezelésére alkalmasak. A találmány szerintikészítmények alkalmazásával a valpronsav és gyógyászatilag elfogadhatószármazékai mellékhatásai és ezeknek egy további terápiás szerrel valókölcsönhatása csökken, valamint hatékonysága nő. Ó
HU0302635A 2000-07-12 2001-07-10 Phospholipid derivatives of valproic acid and mixtures thereof HU229320B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/614,271 US6313106B1 (en) 1995-06-07 2000-07-12 Phospholipid derivatives of valproic acid and mixtures thereof
PCT/IL2001/000629 WO2002007669A2 (en) 2000-07-12 2001-07-10 Phospholipid derivatives of valproic acid and mixtures thereof

Publications (3)

Publication Number Publication Date
HUP0302635A2 true HUP0302635A2 (hu) 2003-11-28
HUP0302635A3 HUP0302635A3 (en) 2007-06-28
HU229320B1 HU229320B1 (en) 2013-10-28

Family

ID=24460534

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302635A HU229320B1 (en) 2000-07-12 2001-07-10 Phospholipid derivatives of valproic acid and mixtures thereof

Country Status (20)

Country Link
US (2) US6313106B1 (hu)
EP (1) EP1315506B1 (hu)
JP (1) JP5140224B2 (hu)
KR (1) KR100801213B1 (hu)
CN (1) CN100536851C (hu)
AT (1) ATE461697T1 (hu)
AU (2) AU7096201A (hu)
BR (1) BR0112337A (hu)
CA (1) CA2415354C (hu)
CY (1) CY1110113T1 (hu)
CZ (1) CZ305745B6 (hu)
DE (1) DE60141636D1 (hu)
DK (1) DK1315506T3 (hu)
ES (1) ES2343403T3 (hu)
HU (1) HU229320B1 (hu)
IL (1) IL153147A0 (hu)
MX (1) MXPA03000326A (hu)
NZ (1) NZ522788A (hu)
PT (1) PT1315506E (hu)
WO (1) WO2002007669A2 (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313106B1 (en) * 1995-06-07 2001-11-06 D-Pharm Ltd. Phospholipid derivatives of valproic acid and mixtures thereof
US6518311B2 (en) * 1997-07-09 2003-02-11 D-Pharm Ltd. Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
US7582678B2 (en) 1997-07-09 2009-09-01 D-Pharm Limited Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
US7217696B2 (en) 2002-02-28 2007-05-15 A & D Bioscience, Inc. Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
WO2003079980A2 (en) * 2002-03-19 2003-10-02 A & D Bioscience, Inc. Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
US20050255038A1 (en) * 2002-04-12 2005-11-17 A And D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents and uses thereof
EP1549323A2 (en) * 2002-05-07 2005-07-06 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
US20050170063A1 (en) * 2004-01-29 2005-08-04 Lalit Chordia Production of powder and viscous material
GB2460976B (en) * 2005-03-24 2010-02-17 John Marcell Davis Methods of determining compounds useful in the treatment of bipolar disorder and methods of treating such disorders
WO2007028030A2 (en) * 2005-09-02 2007-03-08 Picobella, Llc Oncogenic regulatory rnas for diagnostics and therapeutics
US7459280B2 (en) * 2006-02-27 2008-12-02 Picobella, Llc Methods for diagnosing and treating kidney cancer
US20080267977A1 (en) * 2007-04-26 2008-10-30 Friedrich-Alexander University Of Erlangen-Nuremberg Combined immunological agent and sensitizing agent for the treatment of cancer
KR200451744Y1 (ko) * 2008-10-10 2011-01-10 이종희 휴대용 운동기구
CA2872976A1 (en) * 2012-05-08 2013-11-14 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
CN104230981B (zh) * 2013-06-20 2016-05-18 江苏恩华药业股份有限公司 丙戊酸磷脂衍生物的制备方法
IL307857A (en) * 2016-03-16 2023-12-01 Buzzelet Development And Technologies Ltd Cannobinoid compounds are rich in terpenes
CN108659038B (zh) * 2017-03-31 2022-01-11 江苏恩华药业股份有限公司 1-硬脂酰-2-丙戊酰-sn-甘油-3-磷脂酰胆碱的多晶型物及制备方法
CN108659037B (zh) * 2017-03-31 2022-01-11 江苏恩华药业股份有限公司 丙戊酸磷脂衍生物的多晶型物及制备方法
KR101864085B1 (ko) * 2017-09-22 2018-06-01 동아대학교 산학협력단 발프로산 유도체, 이의 제조방법 및 이를 포함하는 항경련제
CN110407867A (zh) * 2018-04-28 2019-11-05 江苏恩华药业股份有限公司 丙戊酸磷脂衍生物的新晶型及其制备方法
CN114344303B (zh) * 2022-01-13 2023-05-09 江苏海洋大学 一种新型精神药物固体分散体及制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654370A (en) * 1979-03-12 1987-03-31 Abbott Laboratories Glyceryl valproates
US5212326A (en) 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
US4988731A (en) 1979-08-20 1991-01-29 Abbott Laboratories Sodium hydrogen divalproate oligomer
US4558070A (en) 1983-10-26 1985-12-10 Abbott Laboratories Acid salts of valproic acid
CA1260393A (en) * 1984-10-16 1989-09-26 Lajos Tarcsay Liposomes of synthetic lipids
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
IT1201149B (it) 1987-01-14 1989-01-27 Indena Spa Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche
WO1989005358A1 (en) 1987-11-30 1989-06-15 University Of Iowa Research Foundation Dna and rna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes
DE3801587A1 (de) 1988-01-21 1989-08-03 Hoechst Ag Neue aminosaeureglyceride, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung
WO1990010448A2 (en) 1989-03-07 1990-09-20 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
JPH03133987A (ja) 1989-10-18 1991-06-07 Kowa Yakuhin Kogyo Kk ２‐マイトマイシンｃ‐スクシニル‐１，３‐ジパルミトイルグリセロールおよびその製造法
WO1991016920A1 (en) 1990-05-07 1991-11-14 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
CH679856A5 (hu) 1990-07-04 1992-04-30 Lonza Ag
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
WO1993000910A1 (en) 1991-07-12 1993-01-21 Vical, Inc. Antiviral liponucleosides: treatment of hepatitis b
US6015834A (en) 1992-10-20 2000-01-18 Toronto Neuroprotection Group In vivo treatment of mammalian cells with a cell membrane permeant calcium buffer
IL105244A (en) * 1993-03-31 2003-07-31 Dpharm Ltd Prodrugs with enhanced penetration into cells
US6413949B1 (en) 1995-06-07 2002-07-02 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
US6313106B1 (en) * 1995-06-07 2001-11-06 D-Pharm Ltd. Phospholipid derivatives of valproic acid and mixtures thereof
IL121268A0 (en) * 1997-07-09 1998-01-04 Dpharm Ltd Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
KR100301803B1 (ko) 1998-06-05 2001-09-22 김영환 박막트랜지스터 및 그의 제조방법

Also Published As

Publication number Publication date
CZ200386A3 (cs) 2003-06-18
KR20030034099A (ko) 2003-05-01
PT1315506E (pt) 2010-05-17
US6313106B1 (en) 2001-11-06
ATE461697T1 (de) 2010-04-15
JP2004509854A (ja) 2004-04-02
IL153147A0 (en) 2003-06-24
HU229320B1 (en) 2013-10-28
JP5140224B2 (ja) 2013-02-06
KR100801213B1 (ko) 2008-02-05
HUP0302635A3 (en) 2007-06-28
BR0112337A (pt) 2004-06-08
CZ305745B6 (cs) 2016-03-02
EP1315506A4 (en) 2005-03-30
AU2001270962B2 (en) 2006-03-16
US20040033987A1 (en) 2004-02-19
CA2415354C (en) 2009-09-29
AU7096201A (en) 2002-02-05
MXPA03000326A (es) 2004-12-13
NZ522788A (en) 2005-04-29
CY1110113T1 (el) 2015-01-14
EP1315506A2 (en) 2003-06-04
CN1774252A (zh) 2006-05-17
CN100536851C (zh) 2009-09-09
WO2002007669A3 (en) 2003-01-09
AU2001270962B8 (en) 2006-08-10
CA2415354A1 (en) 2002-01-31
DK1315506T3 (da) 2010-05-31
EP1315506B1 (en) 2010-03-24
WO2002007669A2 (en) 2002-01-31
DE60141636D1 (de) 2010-05-06
ES2343403T3 (es) 2010-07-30

Similar Documents

Publication Publication Date Title
HUP0302635A2 (hu) Valpronsav foszfolipidszármazékai és ezek keveréke
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
UA70298A (uk) Похідні с-4"-заміщених макролідів, спосіб їх одержання, проміжні сполуки, фармацевтична композиція та спосіб лікування бактеріальної інфекції або протозойної інфекції
AU2002359164A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
BR9810312A (pt) Composição farmacêutica que apresenta atividade antitumoral acentuada e/ou efeitos colaterais reduzidos contendo um agente antitumoral e um derivado do ácido hidroxìmico
IL133585A0 (en) Soluble prodrugs of paclitaxel
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
AP9701019A0 (en) Phenylamino-substituted tricycle derivatives.
MY117892A (en) Therapeutic compounds
LV12766A (lv) Composition of l-dopa esters
EE04238B1 (et) Asendatud 1,2,3,4-tetrahüdronaftaleeni derivaadid, meetod selle valmistamiseks, nimetatud terapeutilise toimega aineid sisaldavad ravimkoostised ja nimetatud aktiivsete ühendite kasutamine teraapias
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
HUP0004282A2 (hu) 2-Halogén-6-0-szubsztituált ketolidszármazékok
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
TR200000149T2 (tr) Serebral nörovasküler bozuklukların, müsküler baş ağrılarının önlenmesine yönelik kompozisyonlar
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
WO2001000617A3 (en) Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the same
MX9805441A (es) Compuestos terapeuticos.
AU5691796A (en) Terpenoidic derivatives useful as antitumor agents
CA2078869A1 (en) Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use
IL109076A0 (en) Imidazolo-quinoxalinones, their preparation and pharmaceutical compositions containing them
AU6826700A (en) Ceramide analogs, process for their preparation and their use as antitumor agents
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
EA200400691A1 (ru) Получение чистых стереоизомеров трицикло[5,2,1,02,6]дец-9-ил-ксантогената и содержащие их лекарственные средства

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees